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Non-conventional MHC class I MIC molecules interact not with the TCR, but with NKG2D, a C-type lectin activatory receptor
present on most NK, cd and CD8
+ ab T cells. While this interaction is critical in triggering/calibrating the cytotoxic activity of
these cells, the actual extent of its in vivo involvement, in man, in infection, cancer or autoimmunity, needs further assessment.
The latter has gained momentum along with the reported expansion of peripheral CD4
+CD28
2NKG2D
+ T cells in rheumatoid
arthritis (RA). We first initiated to extend this report to a larger cohort of not only RA patients, but also those affected by
systemic lupus erythematosus (SLE) and Sjo ¨gren’s syndrome (SS). In RA and SS, this initial observation was further tested in
target tissues: the joint and the salivary glands, respectively. In conclusion and despite occasional and indiscriminate




+ and auto-immunity. Moreover, in situ, the presence of NKG2D matched that of CD8
+, but not that of
CD4
+ T cells. In parallel, a total body tissue scan of both MICA and MICB transcription clearly shows that despite original
presumptions, and with the exception of the central nervous system, both genes are widely transcribed and therefore possibly
translated and membrane-bound. Extending this analysis to a number of human tumors did not reveal a coherent pattern of
expression vs. normal tissues. Collectively these data question previous assumptions, correlating a tissue-specific expression/
induction of MIC in relevance to auto-immune or tumor processes.
Citation: Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S (2007) In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-
Immunity and Cancer. PLoS ONE 2(6): e518. doi:10.1371/journal.pone.0000518
INTRODUCTION
Cytotoxic CD8
+ and helper CD4
+ ab T cells recognize
conventional peptide-loaded Major Histocompatibility Complex
(MHC) class I and II molecules respectively [1]. Whilst the former
interaction leads to the elimination of the virally infected or the
tumorized target cells, the latter, helps amplify/regulate primarily
the humoral immune response against exo or auto-antigens [2,3].
Although this textbook definition of the adaptive immune response
is clear, real life functional/dysfunctional implications of these
interactions, in conjunction with the second, innate, actors of the
immunity, is far from being simple. This is perhaps best
exemplified in auto-immune reactions, where depending on the
disease, the species (human or mouse in essence) and the
experimental model, different components of the immune system
have been sequentially put to the forefront, leading to the logical
assumption that virtually all actors of the immune system are
involved either in triggering and/or perpetuation of the disease
[4–6].
Unlike the above mentioned conventional MHC-I molecules,
MIC molecules [7,8] do not interact with the TCR per se but do so
with NKG2D, a C-type lectin activatory receptor expressed on
NK, cd and CD8
+ ab T cells [9,10]. This interaction has been
shown to over-ride the inhibitory signal provided by Killer
Inhibitory Receptors (KIR) and/or CD94/NKG2A/B molecules
which sense the presence of respectively HLA-ABC and -E on
target cells. While on T cells, NKG2D functions as a co-
stimulatory molecule [11], it may activate NK cells as well as IL-
15-activated intraepithelial T lymphocytes in a TCR independent
fashion [12]. MIC-NKG2D engagement is believed to be
consequently critical in eliminating infected cells and/or tumours
[13,14]. Whether this interaction is also relevant in autoimmunity
is a matter of more recent emphasis [15].
Rheumatoid arthritis (RA) is an archetypical auto-immune
disease and as such resumes our present knowledge and challenges
regarding autoimmunity [16]. A vast body of work has yielded to
numerous hypotheses regarding the initiation and perpetuation of
the disease. Throughout time, T cells or B cells have been
recognized as the primary actors of the disease. The putative
tissue-specific or systemic auto-antigen(s) in man remains elusive,
in contrast to several natural or transgenic/gene targeted animal
models where several self antigens have been recognized to able to
initiate the disease [17]. One of the recent putative actors in RA
pathogenesis has been forwarded as a discrete population of CD4
+
T cells which lack the co-stimulatory molecule CD28 and have
been reported to be expanded in RA [18,19]. More recent
investigations reported that these T cells express, instead of CD28,
the above described NKG2D [15]. The following work was
initiated on this assumption and aimed to first replicate these initial
data in a larger, better defined, cohort of RA patients. It was
further extended to two other auto-immune diseases: systemic
lupus erythematosus (SLE) and Sjo ¨gren’s syndrome (SS). In RA
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expression level in target tissues, both at the messenger RNA and
the protein level. Moreover in peripheral blood besides measuring
the presence of CD4
+NKG2D
+ cells per se, we also set to analyze
the TCR b repertoire of these cells in certain individuals (cf. infra).
Finally, and for the first time, a comprehensive organ/tissue scan
allowed to uncover the fact that in contrast to what was initially
assumed and has since entered textbooks [20], and with the
exception of the central nervous system, MICA and MICB were
transcribed in virtually every tissue/organ examined. The further
extension of this analysis to tumorized samples helped give a better
grasp of MIC transcription in both health and disease.
MATERIALS AND METHODS
Patients and controls
25 healthy volunteers as well as 75 patients suffering from RA
(n=35; 1988 American College of Rheumatology criteria)[21],
SLE (n=15; 1997 revised American College of Rheumatology
criteria)[22] and SS (n=25; 2002 American and European
criteria)[23] were included in this study (Table 1). All samples
were obtained from volunteers attending the Rheumatology clinic
of Strasbourg University Hospitals and were collected during
routine clinical (diagnostic/prognostic/therapeutic) procedures
prescribed by one of the co-authors, Dr. J. Sibilia. Written
informed consent was obtained from each individual in agreement
with the Helsinki Declaration and French legislation, under which
no approval by an ethical committee was required in this case. All
patients and controls were unrelated.
Flow Cytometry
The following, variously conjugated (PE, FITC, PerCP, Cy5 or
APC) antibodies were used in three- and -four-color flow
cytometry: anti -CD3, -CD4, -CD5, -CD8, -CD16, -CD19, -
CD28, -CD45, -CD45RA, CD45RO, -CD56, -CD94, -CD158a, -
CD158b, -NKG2A, -TCR cd. The T cell repertoire was analysed
by the following PE and FITC conjugated anti-TCRVb (1, 2, 3, 4,
5.1, 5.2, 5.3, 7.1, 7.2, 8, 9, 11, 12, 13.1, 13.2, 13.6, 14, 16, 17, 18,
20, 21.3, 22, 23) (Beckman Coulter) antibodies. Isotype-matched
controls were used for each staining. NKG2D expression was
analysed using PE-conjugated ON72 (Beckman Coulter) and
1D11 (BD PharMingen), either PE-conjugated or biotinylated; the
latter detected by streptavidine-PC5 (BD PharMingen). Peripheral
blood cells were studied either unfractionated or after Ficoll
density gradient centrifugation. Mononuclear cells were also
isolated by Ficoll density gradient centrifugation from articular
fluids obtained from 1 RA, 3 osteoarthritis and 2 non auto-
immune arthritis patients. Flow cytometry was performed on
either a BD FACSCalibur
TM (Becton Dickinson) or FC 500
(Beckman Coulter) systems.
Immunohistochemistry
Synovial tissues were obtained from 1 RA elbow and 1 osteoar-
thritis patients at the time of knee arthroplasty. Salivary gland
tissues were obtained from 4 SS and 1 healthy volunteer during
rhinoplasty. For immunohistochemistry, 4 mm cryostat sections
were made from synovial tissues or salivary glands and snap-frozen
in liquid nitrogen. Successive sections were fixed in acetone, air
dried, rehydrated in PBS, and blocked with 0.3% Hydrogen
peroxide. Sections were incubated with anti: -NKG2D mAb 1D11
(BD PharMingen), -MIC mAb 6D4 (BD PharMingen), -CD4, -
CD8 for 1 h at room temperature. Binding was detected using
biotinylated secondary anti-IgG and streptavidin peroxidase.
Sections were counterstained with Harris’ hematoxylin and
mounted with Glycergel.
Northern Blotting
Human mRNA blots were purchased from Invitrogen (Invitrogen
Northern Territories). The membranes were sequentially hybrid-
ized with MICA, b-actin and b2-microglobulin (b2m) cDNAs,
subjected subsequently to high stringency washes (64uC, 0.1XSSC,
0.1% SDS), prior to exposure to Kodak Xomat (Eastman Kodak,
Rochester, NY) for respectively 8h at 270uC, 1 h at room
temperature and 4h at 270uC respectively.
Real-time quantitative PCR
Accessory salivary gland biopsies were obtained from an
independent set of 20 (19 female and one male; average age 51,
median 52) patients with primary SS. Salivary glands from 5
patients undergoing orofacial surgery (for independent causes)
were obtained during the procedures and served as controls while
both pathology as well as patient history further eliminated any
signs of auto-immunity in these control individuals. Total cellular
RNA was isolated by TRIzol LSH (Invitrogen) according to
manufacturer’s recommendations. The quality of extracted RNA
was ascertained through gel electrophoresis. 1 mg of total RNA was
subjected to reverse-transcription using oligo-dT and the ImProm-
II
TM Reverse Transcription System (Promega), following manu-
facturer’s recommendations. Real-time quantitative PCR was
performed on an ABI PRISM 7000 using the following
oligonucleotides and TaqManH probes. The expression levels of
MICA and MICB were calibrated using that of the house keeping
18S RNA detected using the following forward and reverse
Table 1. Characteristics of patients and healthy controls.
......................................................................
Controls RA SLE SS
Individuals (men/
women)
25 (3/22) 35 (5/30) 15 (3/12) 25 (1/24)
Mean age 37.5 (25–58) 49.7 (30–77) 38 (16–70) 56.5 (40–80)
Disease duration
(years)
– 6.8 (1–25) 6.6 (3–16) 11.6 (2–42)
Disease activity* – 4.7 (1.8–7.4) 0.5 (0–5) 64.6 (25–96.6)
No treatment – 5 (14%) 3 (20%) 15 (60%)
NSAID** – 8 (23%) 0 0
Corticosteroids – 12 (40%) 6 (20%) 3 (12%)
SMARD – 7 (20%) 6 (40%) 4 (16%)
DCART – 13 (37%) 6 (40%) 3 (12%)
ANA.320 – 5 (14%) 14 (93%) 15 (60%)
ENA – 0 7 (47%) 12 (48%)
Anti-dsDNA – 0 3 (20%) 0
RF – 21 (60%) 1 (7%) 6 (24%)
Anti-CCP – 15 (43%) 0 0
Joint erosions – 22 (63%) 0 0
*DAS (Disease Activity Score) 28 for RA, SLEDAI (Systemic Lupus Erythematosus
Disease Activity Index) for SLE and mean AVS (AVS: Analogic Visual Scale) of
subjective sicca syndrome, asthenia and pain for SS.
**Abbreviations: NSAID: Non-Steroidal Anti-Inflammatory Drugs; SMARD:
Symptom Modifying Anti-Rheumatic Drugs; DCART: Disease Controlling Anti-
Rheumatic Therapy; ANA: antinuclear antibody (indirect immunofluorescence
on Hep2 cells), ENA: extractable nuclear antigens; dsDNA: double-stranded
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GCTGGAATTACCGCGGCT-59 and SYBR Green. MICA
transcripts were detected using the following forward, reverse
oligonucleotides and TaqManH probe respectively 39-CAGCTG-
CAAACGCCTCATATC-59,3 9-TGACCTATGAAACAGAGA-
AAATAAAAGC-59 and 39-ACATTTTGCAGCCTCCAACAA-
CAATAAATAAGTG-59 and those of MICB with F 39-CACC-
CAGGCTGCAGTTCACT-59,R3 9-CGGGAGTCTGAGGTA-
CGAGAA-59,3 9-ACCTCTGCCTCCCAGGTTCAAGCAC-59
in the same order as above. Positive upregulation of MIC tran-
scription was ascertained in HeLa cells grown untreated or heat
shocked as previously described [24].
RESULTS AND DISCUSSION
Despite the fact that the initial ‘‘glitch’’ triggering auto-immune
diseases in general and rheumatoid arthritis in particular, remains
mostly enigmatic, decades of research have brought together
several plausible scenarios whereas upon initiation, various
pathways and cascades tend to more or less perpetuate an auto-
reactive (T and/or B cell driven) force, eventually leading to
symptomatic pathology [6,25–28]. One of the latest incriminated
T cell subpopulations as such, is the fraction of CD4
+ helper T
cells expressing the activating receptor NKG2D, but devoid of the
co-stimulatory molecule CD28 [15]. NKG2D, a type-II trans-
membrane surface homodimer consists of a C-type lectin extra-
cellular domain, followed by a transmembrane and a short cyto-
plasmic tail devoid of any particular signalling function. The
molecule signals indeed (at least in man) via interaction with the
trans-membrane adaptor protein DAP10 (DAP10 and DAP12 in
mus depending on the NKG2D isoform)[29]. NKG2D recognizes
a variety of distantly related non-conventional MHC class I
molecules; in man MIC [7] and RAET1 [30] (ULBP) [31] and in
mouse RAE1 and H60 [9,29]. The initial aim of this work was to
advance our knowledge of the potential role of the MIC-NKG2D
interaction in autoimmunity in man. In order for such to be the
case, (at least) two conditions should be met: (1) firstly and ideally,
organs target for autoimmunity (hence potentially all organs and/
or tissues), should not express MIC at basal state, in other words,
MIC should be only detected in diseased tissues or pathological
states. (2) secondly that systemic and/or tissue-infiltrated auto-
reactive CD4
+ T cells express NKG2D and be indeed expanded in
such disease; a prelude to their potential functional relevance.
Again and although the textbook definition of MIC expression
is that of quasi-restriction to enterocytes [20,24], the reality is far
from being so clearcut and this reductionist view simply does not
reflect reality (cf. below). Indeed the first monoclonal antibodies
raised against MICA proved to stain preferentially, if not quasi-
exclusively, human enterocytes, with the notable exception of
thymic epithelium [24]. This was in line with initial Northern
blottings highlighting the transcription of the gene, not in cell lines
(transformed) of lymphohematopoeitic lineage, but in those of
epithelial/fibroblastic origin [7]. On the other hand, gene transfer
experiments have clearly shown, over and over, that no matter the
lineage of the recipient cell line, if the transgene (under
a heterelogous promoter that is) is properly transcribed, the
MIC protein is invariably synthesized and reaches cell surface
[24,32–37], hence excluding any cellular ‘‘restriction element(s)’’
such as those precedently shown to be required for the proper
surface expression of other non-classical MHC class I genes e.g.
classical HLA signal sequence derived peptides in case of HLA-E/
Qa-1 in man/mouse [38] or bacterially-derived N-formylated
peptides in case of H2-M3 in mouse [39]. Hence the critical
question is in which tissue/organ MICA and MICB are indeed
transcribed, in which case one could confidently presume their
consequent surface expression. As trivial as this question might
seem, almost 15 years since their identification [7], no systematic
transcriptional analysis of MIC genes has been published to date.
Here we present one first such analysis. Indeed extensive Northern
blotting of a large number of human tissues and organs clearly
indicates that in contrast to previous contentions, both MICA and
MICB are widely transcribed. As seen in Figure 1 (top panel), these
transcripts are found in virtually every organ examined with the
Figure 1. Northern blot analysis of MICA and MICB expression in various healthy organs. The panel represents RNA originating from major human
organs. Each panel contains lung RNA as an internal standard. Top panel was hybridized with MICA cDNA. The differential transcript length of MICA
and MICB is due to a previously documented larger 39UT in MICB mRNA [50]. The middle panel depicts the expression of b2m, indicative of the b2m
bound conventional MHC-I expression. Finally the b-actin transcription acts as a loading control. For more detailed explanation see main text.
doi:10.1371/journal.pone.0000518.g001
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panel, Figure 1). This indeed correlates perfectly with the
transcription pattern of classical MHC-I loci, as evidenced by
probing the same membranes with a b2m cDNA probe (in-
termediate panels, Figure 1). Paying closer attention to MIC
expression pattern, one observes that even an organ ‘‘filled’’ with
lymphohematopoeitic cells - the spleen - is not devoid of MICA
transcripts and contains MICB transcripts in equal amounts as to
other organs (lung, kidney…). Again, the clear absence of MIC
from the central nervous system is remarkable, and indeed
unexpected, in that it clearly parallels that of classical MHC-I
genes (b2m panel) and this despite the fact that at least the
immediate promoter regions of these loci (MIC and conventional
MHC-I) do not show any evident sequence homology [24]. Finally
and in order to cover the grounds as much as possible with regards
to MIC transcription, we extended this transcriptional charting
from healthy to tumorized tissues. A number of tumours of various
tissue types were analyzed and compared to healthy adjacent
tissues (Figure 2). Again, MIC transcription was widely present,
and no general pattern of induction/repression could be observed
in tumours vs. healthy tissues (Figure 2), unlike precedently
suggested [13]. Hence, all in all, MIC is transcribed in virtually
every examined tissue with the notable exception of the central
nervous system. The overall pattern in tumours is indicative of
Figure 2. Northern blot analysis of MICA and MICB expression in various tumors. The same disposition as Figure 1 applies, but this time the blots
contain tumor and control (adjacent disease-free tissue) lanes.
doi:10.1371/journal.pone.0000518.g002
MIC in Cancer and Autoimmunity
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antibodies have apparently shown to depict a restricted tissue
expression pattern must therefore lie elsewhere e.g. genetic
polymorphism [40], various N-linked glycosylation patterns
(MICA has 8 potential N-linked glycosylation sites) [7,24].
Having established that MIC is transcribed and therefore
potentially translated in any/every tissue, we set now to examine
the relevance of MIC and indirectly that of MIC-NKG2D
expression in auto-immunity. For such, three prototypical auto-
immune diseases were selected, because of their inherent relevance
in understanding human auto-immunity [25,41,42], clinical/
medical interest as well as the fact that with respect to RA,




For this analysis the following cohort of individuals were
gathered: 25 healthy controls and 75 patients suffering from the
above mentioned auto-immune disorders i.e. 35 RA, 15 SLE and
25 SS (Table 1). Among these a subgroup including 10 control
individuals, 10 RA, 2 SS and 2 SLE patients were extensively
immunophenotyped with a wide panel of antibodies, in various
combinations, in order to gauge internal standards prior to full
scale effort (see Materials and Methods for the full list of
antibodies). In this way various T, B and NK cell populations
were investigated. No significant difference was observed between
the patient and the control populations (data not shown). More
specifically the distribution of NKG2D at the surface of ab CD8
+
and cd T lymphocytes as well as NK cells, initially tested using
total peripheral blood cell preparations, did not reveal, as
expected, any notable difference between patients and controls.
We then turned our focus to the population of interest i.e.
CD4
+NKG2D
+ T cells (Figure 3). The ratio of NKG2D
expression on CD4
+ T cells was found to be equally similar in
all healthy volunteers (0.8–8.5%, mean 2.7%, standard deviation
2), all RA (0.4–9.7%, mean 2.1%, standard deviation 1.9), all SLE
(0.3–7.8%, mean 2.4%, standard deviation 2) and all SS patients
(0–36.2%, mean 4%, standard deviation 7.6) (Figure 4). Two SS
patients were indeed found to have higher NKG2D expression on
their CD4
+ T cells (18.6% and 36.2% respectively) (see below for
Figure 3. Flow cytometric analysis of the CD4
+NKG2D
+ population. This example, taken from one of the two SS patients (Mrs XET) harbouring
a particularly high ratio of CD4
+NKG2D
+ T cells (36.2%) illustrates the methodology used in order to enumerate these cells in all individuals (controls
and patients) included in this work during a routine 50 000 events analysis.
doi:10.1371/journal.pone.0000518.g003
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such patient). Because a precedent study, which had found
significantly higher CD4
+NKG2D
+ T cells in RA vs. controls, had
used another anti-NKG2D mAb, i.e. 1D11 (BD PharMingen) (vs.
the above used ON72 clone, Beckman Coulter), we also tested this
antibody. Comparison of NKG2D staining with either antibodies
on CD4
+ T cells in 3 healthy volunteers, 4 RA, 1 SLE and 2 SS
did not reveal any significant difference (mean difference : 0.21;
standard deviation: 0.24). Furthermore we also compared this
immunophenotyping comparing total peripheral blood vs. mono-
nuclear cells, using ON72 mAb. This was assessed in 1 healthy
volunteer, 2 RA and 2 SS without hinting to any difference (mean
difference: 0.33; standard deviation: 0.52). Finally and in order to
fully validate the setup, intra-individual stability of NKG2D
expression on CD4
+ T lymphocytes was verified over time in 2
healthy volunteers at respectively days 1/14 and 1/120, for 1 RA
patient at d1/d120 and for 2 SS patients at d1/d150. No notable
differences (mean: 0.31; standard deviation: 0.5) were observed in
different lymphocyte subpopulations and especially those CD4
+ T
cells expressing NKG2D. Given that the same above mentioned
report had hinted to the induction of NKG2D expression on
CD4
+ T cells upon adjunction of TNFa (in vitro), RA patients
under anti-TNFa therapy were not included in this study, despite
the fact that a preliminary analysis of three RA patients treated
with infliximab did not show any significant difference upon the
level of NKG2D expression on CD4
+ T lymphocytes (data not
shown). Hence all in all, we were not able to find any significant
difference between the CD4
+NKGD
+ population in healthy
controls vs. RA, SS or SLE patients. Finally, Figure 5 gives
a complete picture of the CD4
+ T cell pool with regards to
NKG2D and/or presence or absence of CD28.
The end-target in RA being the joint, we set out next to analyze
the CD4
+NKG2D
+ expression levels within mononuclear cells in
the articular fluid harvested after Ficoll density gradient centrifu-
gation from one RA elbow and 5 controls (three knee osteoarthritis
and two non auto-immune knee arthritis) patients. Again no
Figure 4. CD4
+NKG2D
+ T cells autoimmune diseases. This figure
depicts the ratio of CD4
+NKG2D
+ T cells within the total peripheral CD4
pool in control, RA, SLE and SS individuals. The variability in SS patients
is due to 2 individuals whom represent an unusually high ratio (see
main text for explanation). None of the differences is significant as
assessed by the Wilcoxon text: p=0.1658 for controls vs. RA; p=0.9547
for controls vs. SLE and p=0.5012 for controls vs. SS.
doi:10.1371/journal.pone.0000518.g004
Figure 5. Surface phenotype of CD4 T cells with respect to NKG2D and CD28. This, more global figure, analyses the ratio of CD4
+ T cells harbouring
or not CD28 and/or NKG2D, or not. None of the differences is statistically significant.
doi:10.1371/journal.pone.0000518.g005
MIC in Cancer and Autoimmunity
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+ T
cells was highlighted between controls and RA in joint fluids, and
between peripheral blood and joint fluid in one RA patient (data
not shown). To further explore the significance of the expression of
NKG2D on CD4
+ and CD8
+ T cells in situ, synovial tissues were
analyzed by immunohistochemistry in order to quantify the
presence of CD4, NKG2D, CD8 and MICA/B expressing cells.
This was performed in one RA (hip arthroplasty) and one
osteoarthritis control (knee surgery) individual. In the control
individual NKG2D was found to be expressed on 3.8% of
peripheral blood CD4
+ T lymphocytes vs. 2.5% of those found in
the joint fluid. As this individual did not carry any active intra-joint




+ lymphocytes (no MIC
expression was found either in this patient). In the RA patient,
NKG2D was expressed on 0.9% of circulating CD4
+ T cells (no
joint fluid could be retrieved from the RA hip undergoing surgery).
The tissue infiltrate in RA (Figure 6A) was mainly CD4
+
(Figure 6B) whereas CD8 expression was less important
(Figure 6C). NKG2D expression was clearly exclusive of CD4
and more in line with that of CD8 (Figure 6D) (NB.: these are
distinct tissue sections, hence no superimposition is meaningful).
Finally, MICA/B was expressed on fibroblastic/epithelial cells and
not on inflammatory infiltrates (Figure 7A and B).
Although our results in RA are at odds with some of the
previously published data, some clarification of the latter might
help put our results and indeed the whole question in perspective.
Prior to doing such, we clearly do not replicate the work by Groh
et al. with respect to expansion of CD4
+NKG2D
+ in RA although
we did our best to stick to their protocol e.g. using the same anti-
NKG2D antibodies etc. [15]. There might be rational explana-
tions for such, one being lack of any detailed information with
respect to their patient population, for instance the fraction under
anti-TNFa therapy etc. A deeper analysis of the literature indeed
shows that the expansion of this time, CD4
+CD28
2 T cells, is not
as pathognomonic of RA as it might have seemed at the onset
[18]. Indeed a more recent analysis of an independent cohort of
patients clearly shows that half of the patients with RA (n=94)
(according to authors those devoid of nodular RA and sicca
syndrome) did not have a significant increase in their peripheral
CD4
+CD28
2 T cell pool with respect to controls (see Figure 1 in
[43]. Finally Saez-Borderias et al. bring in a new twist to the issue,
by reporting the induction of CD4
+NKG2D
+ T cells in response
to human cytomegalovirus (HCMV), leading to envision the fact
that the previous reported expansions may need to be re-assessed
in the light of the HCMV serological status of the patients and
controls. This also opens the avenue for this subpopulation to
recognize, beyond HCMV, other microbial agents, a point not
tested in previous (and present) studies [44].
To probe the potential significance of CD4
+NKG2D
+ T cells in
the immunopathology of SS, immunohistochemistry was per-
formed on salivary gland tissues aiming to detect CD4, NKG2D,
CD8 and MICA/B. Three SS salivary gland tissues were obtained
by biopsy during hospitalization whereas one control salivary
gland tissue was obtained from an otherwise healthy volunteer
individual during rhinoplasty for independent reasons. In the
control individual, the immunohistochemistry did not reveal the
presence of any notable numbers of CD4, CD8 and/or NKG2D
expressing cells in accord with the absence of any inflammatory
infiltrate; this was equally the case for MICA/B expression (data
not shown). In SS, NKG2D was expressed on respectively 0.4, 0.9,
2% of peripheral blood CD4
+ T lymphocytes. Immunohisto-
chemistry (Figure 8A), focalized on inflammatory infiltrates,
showed that in all 3 patients, CD4 T cells were most prevalent,
again mutually exclusive with CD8 staining (Figure 8B and C).
The amount and repartition of NKG2D expression seemed to be
comparable to that of CD8 but not that of CD4 (Figure 8D, C and
B). Moreover, MICA/B expression was detected on epithelial cells
Figure 6. Immunohistochemistry of RA joint infiltrate. (A) Color stain by Hematoxylin-eosin staining. Immunohistochemical analysis using (B) CD4
(C) CD8 and (D) NKG2D antibodies. The infiltrate is clearly of lymphocytic origin with a majority of CD4 T cells.
doi:10.1371/journal.pone.0000518.g006
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and D).
With regards to SS, given the documented expression of MIC
genes and proteins in epithelial cells [24], putative involvement of
different viruses in SS pathophysiology [45] and the relative ease
to access the target tissue, i.e. salivary glands; we aimed to quantify
the level of MIC transcription in healthy and SS afflicted salivary
glands. This was achieved by real-time quantitative PCR analysis
of MICA and MICB transcripts. Prior to doing such on gland
RNA, the methodology was validated on HeLa cells; documented
to be harbouring MICA/MICB transcripts at significant levels,
where these are regulated by cell stress e.g. heat shock [7,24]. Heat
shock was performed as previously described [24]. With regards to
MICA there was an 8x induction after 15 minutes and 3.56 for
MICB. After 60 minutes the induction remained at 4.56for MICA
and 26for MICB. Typical qRT-PCR plots are shown in Figure 9A
Figure 8. Immunohistochemistry of an accessory salivary gland in Sjo ¨gren syndrome. (A) Color stain by Hematoxylin-eosin staining.
Immunohistochemical analysis using (B) CD4 (C) CD8 and (D) NKG2D antibodies. The infiltrate is clearly of lymphocytic origin with a majority of CD4 T
cells.
doi:10.1371/journal.pone.0000518.g008
Figure 7. MICA expression in Rheumatoid Arthritis synovitis and Sjo ¨gren syndrome accessory salivary glands. Immunohistochemical analysis of
(A) (B) RA synovitis and an (C) (D) SS accessory salivary gland stained with an anti-MICA monoclonal antibody. MIC expression is clearly of epithelial/
fibroblastic nature in both tissues/organs.
doi:10.1371/journal.pone.0000518.g007
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a clear inter-individual variability, no significant difference could be
observed between patients and controls (Figure 10A and B).
As alluded to above, among all 75 patients analysed, two SS
patients (Mrs. XET and XRL; in this order in this paragraph) did
indeed present a particularly high rate of CD4
+NKG2D
+ T
lymphocytes in peripheral blood (respectively 36.2% and 18.6%).
No correlation with age, disease duration, disease activity or
treatment was found, and at this stage we consider this pheno-
menon as fortuitous. These two patients provided nevertheless
material to do an extended phenotyping on this peculiar T cell
population: 97% and 94% of these CD4
+NKG2D
+ Tl y m p h o c y t e s
lost CD28, whereas 42.5% and 67.3% expressed CD45RA.
Moreover they were negative for CD158a (0.2% and 0.4%),
CD158b (0.8% and 0.8%), NKG2A (1.1% and 1.3%) and CD94
(9.1% and 1.3%). The TCR repertoire was analyzed by flow
cytometry using 24 Vb sub-types. For Mrs. XET, regarding the
CD4
+NKG2D
+ cells, three Vb sub-types were expanded and
represented the majority of Vb subtypes (Vb 13.2 : 19.1%, Vb 5.2 :
16.6%, Vb 21.3 : 15.4%). For Mrs. XRL, 69% CD4
+NKG2D
+ T
lymphocytes expressed Vb 7.1. So, CD4
+NKG2D
+ Tl y m p h o c y t e s
expansion seems to have an oligoclonal or monoclonal repartition,
the significance of which at this point remains to be established (cf.
infra: conclusion) (by immunohistochemistry, NKG2D expression on
Mrs. XRL salivary gland tissue was not increased and was
superimposable to CD8 expression but not to CD4’s - data not
shown). In the control group, one individual (Mrs Q) with an above
baseline CD4
+NKG2D
+ T cell count of 8.5% was also further
analyzed. 91% of these cells had indeed lost CD28 expression. The
repertoire ofthese cellswas biclonal - 41%Vb13.1 and17%Vb 13.6
-i nc o n t r a s tt ot h a to fC D 4
+NKG2D
2 within this same individual
(as well as the 2 patients) which did not deviate from the normal
range as provided by the Vb panel manufacturer. Therefore it seems
clear that while CD4
+NKG2D
+ T cells are devoid of CD28 (in line
with previous findings) this is irrespective of the disease status. This is
equally the case for their mono/oligoclonal repertoire.
In conclusion, the sum of this a priori diverse set of information
presented here may help to set the record straight as to the
following: (1) In contrast to what was/is originally/presently
assumed and widely written, MIC transcription (and for reasons
argumented above, translation and surface expression) is not
exclusive of enterocytes as virtually every tissue, organ (exception
of CNS) does harbour MIC transcripts [24,46–49]. It could very
well be that within each organ, the transcripts are solely
contributed by epithelial and/or endothelial cells, but that would
still be in starch contrast to an enterocyte specific expression pattern,
Figure 9. Expression analysis of MICA and MICB by real-time quantitative PCR in HeLa cells. MICA (A) and MICB (B) expression profile as analyzed
by RT-qPCR. & Samples 15 minutes after heat shock, ¤ Samples 60 minutes after heat shock, m untreated controls.
doi:10.1371/journal.pone.0000518.g009
Figure 10. Expression analysis of MICA and MICB by real-time quantitative PCR in Sjo ¨gren’s syndrome accessory salivary glands. Relative
expression level of MICA (A) and MICB (B) in Sjo ¨gren’s syndrome patients as compared to healthy controls. The differences between patients and
controls are not significant as assessed by Mann-Whitney U test (a=0.27 for MICA and a=0.53 for MICB).
doi:10.1371/journal.pone.0000518.g010
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same transcription pattern in various tumors helped also nuance the
‘‘black and white’’ message that MIC is specifically upregulated in
tumors - which is clearly not the case [13]. (3) Finally, it seems clear
that CD4
+NKG2D
+ Tc e l l s-m o s t l yC D 2 8
2 - are not more
prevalent in RA, SLE or SS than in disease-free control individuals.
The expansion of these cells in certain individuals, irrespective of
health/auto-immune disease, might be due to their recognition of
HCMV and/or other infectious agents possibly explaining their
mono/oligoclonal T cell repertoire.
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